Company Filing History:
Years Active: 2018
Title: Inventor Arsalan S Haqqani: Pioneering Advances in Blood-Brain Barrier Research
Introduction
Arsalan S Haqqani, based in Kanata, Canada, is an accomplished inventor with a remarkable portfolio of three patents. His groundbreaking work focuses on the intricate mechanisms of the blood-brain barrier (BBB) and the development of innovative methods to enhance therapeutic delivery to the brain.
Latest Patents
Haqqani's latest patents revolve around insulin-like growth factor 1 receptor (IGF1R)-specific antibodies and their applications. The BBB poses a significant challenge for transporting therapeutic molecules larger than 500 Daltons from the bloodstream to the brain. Haqqani's research has identified receptor-mediated transcytosis (RMT) as a viable pathway for this transport, achieved through specific antibodies that bind to receptors on brain endothelial cells. His innovations include a unique insulin-like growth factor 1 receptor-binding antibody or fragment that can traverse the BBB, facilitating the delivery of therapeutic or detectable cargo molecules across this critical barrier. Notably, these antibodies are derived from camelid VHH, created through the immunization of llamas with a 933-amino acid IGF1R polypeptide. Furthermore, humanized forms of these camelid VHHs have also been developed, showcasing Haqqani's commitment to advancing this field.
Career Highlights
Arsalan S Haqqani is associated with the National Research Council of Canada, where his intellectual contributions have not only advanced scientific understanding but have also paved the way for therapeutic innovations that address critical health challenges. His research illustrates an exceptional blend of creativity and scientific rigor, placing him among notable inventors in biomedical research.
Collaborations
Throughout his career, Haqqani has collaborated with esteemed scientists such as Danica Stanimirovic and Kristin Kemmerich. These partnerships highlight the collaborative spirit underpinning much of scientific innovation, as diverse expertise comes together to tackle complex issues surrounding drug delivery and brain health.
Conclusion
In summary, Arsalan S Haqqani's contributions to the field of neuroscience and biomedicine through his significant patents on IGF1R-specific antibodies represent a crucial step forward in overcoming barriers to brain therapeutics. His ongoing work at the National Research Council of Canada reflects a dedicated pursuit of knowledge and innovation, promising advancements that could profoundly impact medical treatments and patient outcomes.